Abstract:
Embodiments in accordance with the present invention provide for a palladium complex characterized by the general formula: where A is a bidentate monoanionic ligand, NHC is a nucleophilic heterocyclic carbene, and Z is an anionic ligand. Such palladium complexes are useful in initiating cross-coupling reactions.
Abstract:
One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.
Abstract:
A compound of formula (I) or (II): wherein A is hydrogen or CR1R2; Y and Z are each, independently, hydrogen or a halogen; X is —NR4R5, or R7; R1 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1-4 carbon atoms; when X is —NR4R5, R2 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms; when X is R7, R2 is an unsubstituted alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms; R3 is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms; R4 is hydrogen, a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl aralkenyl, or aralkynyl group, that optionally includes at least one heteroatom in its carbon skeleton and contains 1-12 carbon atoms, —COOR8, or —COR8; R5 is hydrogen, or a substituted or unsubstituted alkyl or alkenyl group containing 1-5 carbon atoms; R7 is an unsubstituted alkyl, alkenyl, or alkynyl group, that contains 1-4 carbon atoms; and, R8 is an unsubstituted or halo-substituted alkyl, aryl, or aralkyl group, that contains 1-12 carbon atoms.
Abstract translation:式(I)或(II)的化合物:其中A是氢或CR 1 R 2; Y和Z各自独立地为氢或卤素; X是-NR 4 R 5或R 7; R 1是氢或含有1-4个碳原子的取代或未取代的烷基或链烯基; 当X是-NR 4 R 5时,R 2是取代或未取代的烷基,烯基,炔基,芳基,芳烷基芳烯基或芳炔基 基团,其任选地在其碳骨架中包含至少一个杂原子并且含有1-12个碳原子; 当X是R 7时,R 2是未取代的烷基,烯基或炔基,或取代或未取代的芳基,芳烷基芳烯基或芳炔基,其任选地包括在 其碳骨架中至少有一个杂原子,含有1-12个碳原子; R 3是取代或未取代的烷基,烯基,炔基,芳基,芳烷基芳烯基或芳炔基,其任选地在其碳骨架中包含至少一个杂原子并含有1-12个碳原子; R 4是氢,取代或未取代的烷基,烯基,炔基,芳基,芳烷基芳烯基或芳炔基,其任选地在其碳骨架中包含至少一个杂原子并含有1-12个碳原子, -COOR 8或-COR 8; R 5是氢或含有1-5个碳原子的取代或未取代的烷基或链烯基; R 7是含有1-4个碳原子的未取代的烷基,烯基或炔基; R 8是含有1-12个碳原子的未取代或卤素取代的烷基,芳基或芳烷基。
Abstract:
The invention relates to novel phosphane ligands of formula (Ia) and (Ib): (adamantyl)nP(alkyl)m(1a); (adamantyl)o(Alkyl)qP (alkylennull)P(adamantyl)r(alkyl)s (1b), wherein adamantyl represents an adamantyl radical (IIa, IIb) bonded to the phosphorous atom in position 1 or 2. The invention also relates to the production and use of the above-mentioned ligands in the presence of transitional metal compounds of the 8th. Subgroup of PSE for catalytic reactions, particularly for the refining of halogen aromatics for producing aryl olefins, dienes, diarylene, benzoic acid and acrylic acid derivatives, aryl alkanes and also amines.
Abstract:
The present invention relates to compounds containing a cyclobutanone group of the formula I 1 where the various parameters are as defined in the text, and to liquid-crystal media which comprise these compounds, and to their use in electro-optical displays, in particular in PA LCDs.
Abstract:
The invention relates to the use of substituted cyclopentane-diones and cyclopentane-triones for the preparation of medicaments which as chloride channel blockers are suitable for controlling airway diseases, secretory diarrhea and inflammatory diseases.
Abstract:
A novel imidazole derivative of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group or a salt thereof, and a pharmaceutical composition containing the same as the active ingredient.
Abstract:
A method of inhibiting aromatase, comprising administering to a mammal in need thereof a pharmaceutical composition comprising an effective aromatase inhibiting amount of a compound of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Abstract:
Compound of formula (I): ##STR1## in which: R.sub.1 represents halogen, or hydroxy, alkyl, alkoxy, cyano, amino, mercapto, alkylthio or phenoxy,R.sub.2 and R'.sub.2 represent two hydrogen when the ring is unsaturated, or alternatively identical or different, represent hydrogen or halogen, or hydroxy, alkyl, alkoxy, cyano, amino or oxo when the ring is saturated,R.sub.3 represents any one of the following groups: ##STR2## in which: m represents 1, 2 or 3,X represents oxygen or sulfur or N-R, R.sub.5 or R.sub.6, which are identical or different, represent hydrogen or alkyl or trifluoromethyl or form (C.sub.3 -C.sub.6) cycloalkyl,n represents 0, 1 or 2,R.sub.7 represents hydroxy, alkoxy, amino, or --O--CH.sub.2 --CO--NRR',R.sub.4 represents hydrogen or halogen or alkyl, alkoxy or trihaloalkyl.
Abstract translation:式(I)化合物:其中:R 1表示卤素,或羟基,烷基,烷氧基,氰基,氨基,巯基,烷硫基或苯氧基,当环为不饱和时,R 2和R'2表示两个氢 或者相同或不同,当环饱和时,R 3表示氢或氢,羟基,烷基,烷氧基,氰基,氨基或氧代,R 3表示以下基团中的任何一个:CO 2 H CONHCH 2 CO 2 H(CH 2)m CO 2 H